Psychopharmacology

Now more than ever, capturing and scaling the ingredients that make for compelling and impactful teaching for trainees is vital to our future.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

Dr Nassir Ghaemi explores the long-term effects and safety of serotonin reuptake inhibitors, revealing benefits and potential risks.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.

Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

In response to the threats associated with "DIY psychiatry," experts call for a renewed focus on collaboration and shared decision-making.

Deprescribing: a critical practice in medicine, emphasizing thoughtful medication management and patient-centered care for optimal health outcomes.

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Without the scaffolding of the REMS requirement for clozapine, how can you best utilize this treatment?

How can you best transition patients to Cobenfy if they are already taking an antipsychotic medication?

Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.

Learn more about recent research into adolescent mental health, including a pilot study testing the use of short-term trauma stabilization techniques with escitalopram.

Dennis S. Charney, MD, celebrates the 40th anniversary of Psychiatric Times discussing the history of psychiatry and where he hopes the future lies.

A recent meta-analysis compares efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for adults with ADHD.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

Here are 10 things to consider when treating a patient with mood disorders.

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

Antipsychiatry’s animus toward psychiatric medication has both ancient and modern parallels.